Novel CAR T cell therapy offers promising option for hard-to-treat kidney cancer
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, and patients who progress on standard therapies have limited options and very poor prognoses
The CD70-targeting CAR T cell therapy, ALLO-316, demonstrated encouraging results in previously treated patients with advanced ccRCCÌý
Data demonstrates a great potential to advance cell therapies in the treatment of solid tumorsÌý
Experimental cell therapy delivers encouraging results for patients with rare, potentially fatal brain infection
No approved treatments exist for progressive multifocal leukoencephalopathy (PML), a serious neurological condition caused by the JC virus...
Lower trust in doctors and health agencies linked to gaps in awareness that HPV causes cervical cancer
U.S. adults with less trust in government health agencies or doctors were less likely to be aware that HPV causes cervical cancer, study...
EHA: Oral combination shows high response rates in patients with hard-to-treat acute myeloid leukemia
Relapsed or refractory acute myeloid leukemia (AML) represents one of the most challenging hematologic cancers
The menin inhibitor revumenib was approved by the FDA as a monotherapy in November 2024, but responses to monotherapy can be short-lived
An all-oral revumenib-based combination therapy demonstrated a 71% composite complete remission rate in patients with hard-to-treat AML and specific genetic alterations
ABSTRACT: EHA-5060<...
ASCO: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer
Sunvozertinib is an oral pill targeting specific forms of mutant EGFR, made by Dizal Pharmaceutical
Phase 3 WU-KONG28 trial evaluated...
Direct-to-consumer pharmacies may lower costs for generic prescriptions
Study compared direct purchase prices from Mark Cuban Cost Plus Drug Company to cost-sharing under employer-sponsored insurance
Researchers...
Combination treatment benefits patients with advanced breast cancer that has spread to brain
Ìý
Leptomeningeal metastasisÌýoccursÌýwhen cancer spreads to the thin layers ofÌýtissueÌýand fluid that surround...
Americans prefer to screen for cervical cancer in-clinic vs. at home
More than 60% of American women prefer to get their cervical cancer screening in a clinic versus at home with a self-sampling kit, study finds...
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
Lynch Syndrome significantly increases the lifetime risk of developing multiple cancers, including colorectal and endometrial Ìý
NOUS-209...
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and notÌýtheÌýtype, of bacteria insideÌýtumors can predict response to treatmentÌýin lab...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
PerioperativeÌýnivolumabÌýplusÌýneoadjuvantÌýchemotherapyÌýimprovedÌýoutcomes forÌýpatientsÌýregardless of...
SABCS 2025: Diagnostic breast MRI may be unnecessary for some patients with early-stage breast cancer
Study finds pre-surgical MRI does not improve five-year rates of local regional free survival over mammograms alone in patients with stage...
Traces of bacteria inside brain tumors may affect tumor behavior
Researchers found bacterial genetic and cellular elements inside brain tumor cells that appear biologically active and may influence tumor...
Americans have widespread misbeliefs about the cancer risks of alcohol, study finds
Ìý
More than half of American adults misunderstand or underestimate the link between alcohol consumption and cancerÌý...
ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene...
ESMO 2025: Targeted therapy plus radiation or surgery improves outcomes in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) the most common formÌý
Study reveals how bacteria in tumors drive treatment resistance in cancer
Researchers uncovered a previously unknown way for microbes within tumors to contribute to treatment resistance in certain cancers...
WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers ofÌýnon-small cell lung cancer (NSCLC), yet first-line targeted therapy options...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC)Ìýremains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies...